# Ruxolitinib in Patients With Breast Cancer

> **NCT01562873** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01562873
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2015-06
- **Final completion:** 2016-06
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Not enough responses to continue treatment.
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562873, "Ruxolitinib in Patients With Breast Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT01562873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*